Current management of onychomycosis.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18762123.
- Also identified by DOI 10.1016/j.jhsa.2008.05.028.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Onychomycosis is the most common single cause of nail dystrophy and has a marked impact on quality of life. The availability of newer topical and systemic antifungal agents has improved our ability to effectively treat this condition. This article will review the most commonly used therapies and discuss the relative advantages and disadvantages of different treatment strategies.
Medical subject headings
- Antifungal Agents
- Onychomycosis